Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 27

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 27
---
#### Board’s Oversight of Strategy
The Board is deeply engaged and involved in overseeing our long-term strategy, including evaluating key market opportunities, patient trends and competitive developments. This also includes aspects of our environmental, social and governance (ESG) initiatives that relate to our strategy. The Board’s oversight of risk is another integral component of the Board’s oversight and engagement on strategic matters. Strategy-related matters are regularly discussed at board meetings and, when relevant, at Committee meetings. We also dedicate at least one board meeting every year to an even more intensive review and discussion of our strategic plan. Matters of strategy also inform committee-level discussions of many issues, including enterprise risk. Engagement of the Board on these issues and other matters of strategic importance continues in between meetings, including through updates to the Board on significant items and discussions between the Chief Executive Officer and our Chair on a periodic basis. Each director is expected to and does bring to bear their own talents, insights, and experiences to these strategy discussions.

#### Stockholder Engagement Program
Our relationship with our stockholders is an important part of our corporate governance program. We regularly engage with our stockholders to solicit their feedback on key topics, including executive compensation, corporate governance, ESG initiatives, and overall company strategy. The insights gained from these discussions are highly valued and help ensure stockholder perspectives are considered in our governance, compensation, and sustainability initiatives. Our commitment to transparency and responsiveness helps us align our policies and practices with the interests of our investors, reinforcing our dedication to long-term value creation.

In 2024, we engaged with stockholders whose ownership, in aggregate, represented greater than 70% of our shares outstanding as of December 31, 2024. The outreach included discussions regarding, among other things, our corporate strategy, business development, governance matters, and Company developments.

We believe that the voting results for our Board nominees at the 2024 Annual Meeting may have been negatively impacted by concerns regarding certain anti-takeover provisions in our governing documents (including our classified board structure and supermajority voting requirements to amend our governing documents). We are aware that proxy advisory firms and certain institutional investors deem these anti-takeover provisions to adversely impact stockholder rights. Our Nominating Committee continues to review and assess our governance framework, including these anti-takeover provisions, in the context of our stage of development, stockholder feedback, best practices, and industry trends. The Nominating Committee also considers the prevalence of the anti-takeover provisions among similarly situated companies in our industry. Our